Home・Elenco Azioni・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

4.38 8.68

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.03

Massimo

4.43

Metriche Chiave
By Trading Economics
Entrata	11M 51M
Vendite	6.5M 113M
P/E Media del settore	4.553 51.78
EPS	0.31
Margine di Profitto	45.374
Dipendenti	100
EBITDA	6.6M 81M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+48.88% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-156M 572M
Apertura precedente	-4.3
Chiusura precedente	4.38

Ironwood Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 nov 2026, 22:41 UTC

Ironwood Pharmaceuticals, Inc. shares declined in after-market trading, reaching their lowest level since Friday's close following a sharp retracement from earlier gains.

5 nov 2026, 21:04 UTC

News

Ironwood Pharmaceuticals reported a 49% year-over-year increase in Q3 net income to $59.8 million and raised its 2026 revenue guidance to $485 million-$510 million.

4 nov 2026, 23:16 UTC

Ironwood Pharmaceuticals, Inc. is trading higher in after-market hours, maintaining a position above its 20-day moving average despite a recent decline from an early high.

3 nov 2026, 21:07 UTC

Ironwood Pharmaceuticals, Inc. is trading higher, having gained since Monday's close, despite retracing from an early session peak.

2 nov 2026, 23:06 UTC

Ironwood Pharmaceuticals, Inc. traded modestly higher in after-market hours following Monday's close amid mixed broader market signals and economic data.

30 ott 2026, 22:56 UTC

Ironwood Pharmaceuticals, Inc. shares are trading modestly higher in after-market hours, improving from earlier levels but remaining below their 20-day moving average.

28 ott 2026, 19:46 UTC

Ironwood Pharmaceuticals, Inc. is trading higher, having peaked in late trading.

26 ott 2026, 19:46 UTC

Ironwood Pharmaceuticals Inc is trading roughly flat, showing little significant movement since Friday's close and remaining below its 20-day moving average.

23 ott 2026, 21:26 UTC

Ironwood Pharmaceuticals Inc shares advanced modestly during after-market hours on Friday, reaching a peak return since Friday's close.

22 ott 2026, 19:46 UTC

Ironwood Pharmaceuticals Inc is trading roughly flat, remaining below its 20-day moving average and near the lower end of its one-month range.

21 ott 2026, 22:26 UTC

Ironwood Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase from its earlier low since Wednesday's close.

16 ott 2026, 19:51 UTC

News

Ironwood Pharmaceuticals announces Tammi Gaskins will succeed Tom McCourt as CEO effective January 1, 2027, raising investor concerns about the company's future direction.

15 ott 2026, 20:07 UTC

Ironwood Pharmaceuticals Inc shares are advancing, peaking around midday amid a broader market rise, though still below its 20-day moving average.

14 ott 2026, 20:07 UTC

Ironwood Pharmaceuticals Inc shares are modestly higher.

13 ott 2026, 22:31 UTC

Ironwood Pharmaceuticals Inc is trading modestly higher in after-market hours, recovering from a low earlier in the session after three consecutive declines.

12 ott 2026, 21:01 UTC

Ironwood Pharmaceuticals Inc shares advanced in after-market trading following Monday's close, maintaining stability.

8 ott 2026, 20:07 UTC

Ironwood Pharmaceuticals Inc shares are advancing, recovering from earlier losses, but remain 4.66% below their 20-day moving average.

7 ott 2026, 23:00 UTC

Ironwood Pharmaceuticals Inc is down significantly in after-market trading, falling sharply from earlier gains and currently below its 20-day moving average.

6 ott 2026, 19:35 UTC

Ironwood Pharmaceuticals Inc is trading roughly flat, remaining below its 20-day moving average and near the lower end of its one-month range.

5 ott 2026, 22:25 UTC

Ironwood Pharmaceuticals Inc. is trading modestly higher in after-market hours, maintaining a cumulative return after initially peaking earlier in the session.

2 ott 2026, 23:55 UTC

Ironwood Pharmaceuticals Inc's shares traded roughly flat in after-market hours, following recent lower closes amid broader market trends in labor force engagement and wage growth.

1 ott 2026, 22:01 UTC

Ironwood Pharmaceuticals Inc is trading modestly lower in after-market hours, marking a fourth consecutive session of decline and remaining below its 20-day moving average.

24 set 2026, 19:25 UTC

Ironwood Pharmaceuticals Inc shares fell sharply, retracing from an initial peak and remaining below the previous close and 20-day moving average.

18 set 2026, 20:02 UTC

Ironwood Pharmaceuticals Inc is advancing, continuing a higher trend since Thursday's close, despite currently trading lower in today's market.

17 set 2026, 20:08 UTC

Ironwood Pharmaceuticals Inc is advancing, reflecting broader market gains, despite earlier pulling back amid profit-taking during Thursday's trading session.

16 set 2026, 23:51 UTC

Ironwood Pharmaceuticals Inc is trading modestly lower in after-market hours, positioned below its 20-day moving average and around the midpoint of its one-month trading range.

15 set 2026, 22:11 UTC

Ironwood Pharmaceuticals shares are lower in after-market trading, reflecting volatility amid broader market caution as Treasury yields rise. No specific news was identified.

14 set 2026, 23:16 UTC

Ironwood Pharmaceuticals Inc's shares are lower in after-market hours, with no specific news identified to explain the decline. The stock is below its 20-day moving average.

11 set 2026, 21:01 UTC

Ironwood Pharmaceuticals shares are lower in after-market hours, continuing a decline since Friday's close and trading well below the 20-day moving average.

1 set 2026, 19:46 UTC

Ironwood Pharmaceuticals Inc is trading higher, recovering from earlier session lows while remaining above its 20-day moving average. No specific news was identified.

Confronto tra pari

Modifica del prezzo

Ironwood Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

48.88% in crescita

Previsioni per 12 mesi

Media 6 USD 48.88%

Alto 6 USD

Basso 6 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ironwood Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Ironwood Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.